Lyxumia
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Esses autores, dois dos quais reportam laços significativos com a indústria, sistematicamente revisaram vários bancos de dados…
Lixisenatide is a new GLP‐1 mimetic for use in type 2 diabetes with oral agents and/or insulin. In our New products review, Steve…
Rev Med Liège 2014; 69 : 2 : 102-109 Résumé : Le lixisénatide (Lyxumia) est un nouvel agoniste des récepteurs du Glucagon-Like…
: Lixisenatide (Lyxumia) is a new agonist of Glucagon-Like Peptide-1 (GLP-1) receptors that is indicated in the treatment of type…
Lixisenatide (Lyxumia) is a new agonist of Glucagon-Like Peptide-1 (GLP-1) receptors that is indicated in the treatment of type 2…
Neu auf dem Markt Prandialer GLP-1-Agonist ist ein guter Partner des Basalinsulins _ Wenn in der Therapie des Typ-2-Diabetes…
Paris, France – October 2, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced results from a study showing that the…